A Study of LNCB74 in People With Solid Tumor Cancer

Full Title

A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study for LNCB74, A B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors

Purpose

To learn more about the purpose of this study and to find out who can join, please click here to visit ClinicalTrials.gov for a full clinical trial description.

Contact

For more information or to see if you can join this study, please call Dr. Nicholas Mai’s office at 646-888-4322.